These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 18708261

  • 1. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S.
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [Abstract] [Full Text] [Related]

  • 2. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 3. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients.
    Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S.
    Retina; 2006 Oct; 26(8):871-6. PubMed ID: 17031285
    [Abstract] [Full Text] [Related]

  • 4. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N, Otsuka H, Yamakiri K, Sonoda Y, Nakao S, Noda Y, Hashiguchi T, Maruyama I, Sakamoto T.
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
    Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y.
    Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
    [Abstract] [Full Text] [Related]

  • 8. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.
    Sato T, Kusaka S, Shimojo H, Fujikado T.
    Ophthalmology; 2009 Sep; 116(9):1599-603. PubMed ID: 19371954
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
    Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.
    Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y, Zhang Y, Zhao T, Jiang YR.
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum.
    Bhatnagar P, Freund KB, Spaide RF, Klancnik JM, Cooney MJ, Ho I, Fine HF, Yannuzzi LA.
    Retina; 2007 Sep; 27(7):897-902. PubMed ID: 17891014
    [Abstract] [Full Text] [Related]

  • 15. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration.
    Goverdhan SV, Lochhead J.
    Br J Ophthalmol; 2008 Feb; 92(2):210-2. PubMed ID: 17965104
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.